MA40535A - Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 - Google Patents

Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90

Info

Publication number
MA40535A
MA40535A MA040535A MA40535A MA40535A MA 40535 A MA40535 A MA 40535A MA 040535 A MA040535 A MA 040535A MA 40535 A MA40535 A MA 40535A MA 40535 A MA40535 A MA 40535A
Authority
MA
Morocco
Prior art keywords
hsp90
therapy
inflammation
infection
infection imaging
Prior art date
Application number
MA040535A
Other languages
English (en)
Inventor
Gabriela Chiosis
Mark Dunphy
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MA40535A publication Critical patent/MA40535A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/0275—Measuring blood flow using tracers, e.g. dye dilution
    • A61B5/02755—Radioactive tracers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
    • A61B5/0813—Measurement of pulmonary parameters by tracers, e.g. radioactive tracers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4222—Evaluating particular parts, e.g. particular organs
    • A61B5/4255—Intestines, colon or appendix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/44—Constructional features of apparatus for radiation diagnosis
    • A61B6/4417—Constructional features of apparatus for radiation diagnosis related to combined acquisition of different diagnostic modalities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/503—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5288—Devices using data or image processing specially adapted for radiation diagnosis involving retrospective matching to a physiological signal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/54—Control of apparatus or devices for radiation diagnosis
    • A61B6/541—Control of apparatus or devices for radiation diagnosis involving acquisition triggered by a physiological signal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1884—Nanotubes, nanorods or nanowires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)

Abstract

L'invention concerne de nouvelles méthodes d'imagerie d'une inflammation et d'une infection et des applications médicales associées. Dans certains modes de réalisation, l'invention concerne une méthode pour diagnostiquer une inflammation et/ou une infection. Dans certains modes de réalisation, l'invention concerne une méthode pour traiter ou prévenir l'inflammation et/ou l'infection. Dans certains modes de réalisation, la présente invention concerne des méthodes permettant de surveiller l'effet du traitem
MA040535A 2014-09-17 2015-09-17 Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90 MA40535A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051590P 2014-09-17 2014-09-17

Publications (1)

Publication Number Publication Date
MA40535A true MA40535A (fr) 2016-03-24

Family

ID=55533863

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040535A MA40535A (fr) 2014-09-17 2015-09-17 Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90

Country Status (12)

Country Link
US (3) US10617772B2 (fr)
EP (1) EP3194975A4 (fr)
JP (1) JP6835709B2 (fr)
KR (1) KR20170052687A (fr)
CN (2) CN107110869B (fr)
AU (2) AU2015317632B2 (fr)
BR (1) BR112017005313A2 (fr)
CA (1) CA2961499A1 (fr)
EA (1) EA201790444A1 (fr)
MA (1) MA40535A (fr)
MX (1) MX2017003513A (fr)
WO (1) WO2016044629A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012282903A1 (en) 2011-07-08 2014-02-13 Sloan-Kettering Institute For Cancer Research Uses of labeled HSP90 inhibitors
BR112016014758A8 (pt) 2013-12-23 2020-06-02 Memorial Sloan Kettering Cancer Center composto e método para a marcação radioativa e composição farmacêutica compreendendo o referido composto
MX2017003513A (es) * 2014-09-17 2017-07-28 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia.
WO2018048882A1 (fr) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Composition d'agent d'imagerie par tomographie par imagerie de positrons et méthode pour infection bactérienne
SG11201908670SA (en) 2017-03-20 2019-10-30 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
EP3852791B1 (fr) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activation de la pyruvate kinase r
CN113166060B (zh) 2018-09-19 2024-01-09 诺沃挪第克健康护理股份公司 用丙酮酸激酶激活化合物治疗镰状细胞病

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1437145A1 (fr) * 2003-01-07 2004-07-14 Schering AG Agents scintigraphiques améliorés pour l'imagerie des infections et inflammations
CA2524072A1 (fr) 2003-05-01 2004-11-11 University Of Liverpool Procede de criblage permettant l'identification de modulateurs de hsp90
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006098761A2 (fr) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Inhibiteurs hsp90, procedes de realisation et d'utilisation correspondants
EP1879863A1 (fr) 2005-05-03 2008-01-23 Pfizer, Inc. Composes d'amide resorcinol
US20090215777A1 (en) 2005-05-19 2009-08-27 Astex Therapeutics Ltd. Pyrimidine Derivatives As HSP90 Inhibitors
WO2006130469A1 (fr) * 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation de la croissance des neurites au moyen de molecules de petite taille
EP2007767B1 (fr) 2006-03-11 2011-11-02 Vernalis (R&D) Ltd Derives de pyrrolopyrimidine en tant qu'inhibiteurs de hsp90
CN101490052B (zh) 2006-05-12 2012-08-08 美瑞德生物工程公司 治疗性化合物及其在癌症中的用途
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
EP2034839B1 (fr) * 2006-06-30 2017-08-23 Sloan-Kettering Institute for Cancer Research Traitement de maladies neurodégénératives par l'inhibition de hsp90
WO2008093075A2 (fr) 2007-02-01 2008-08-07 Astrazeneca Ab Dérivés de 5,6,7,8-tétrahydroptéridine comme inhibiteurs de hsp90
MY148860A (en) 2007-03-20 2013-06-14 Curis Inc Fused amino pyridine as hsp90 inhibitors
US8524712B2 (en) 2007-03-27 2013-09-03 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as HSP90 inhibitors
SG187502A1 (en) 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
FR2932484B1 (fr) 2008-06-16 2010-06-18 Sanofi Aventis Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation
RU2011126254A (ru) 2008-11-28 2013-01-10 Новартис Аг Применение ингибтиторов hsp90 для терапевтического лечения
ES2533954T3 (es) 2009-04-21 2015-04-16 Nerviano Medical Sciences S.R.L. Derivados de resorcinol como inhibidores de HSP90
BR112012003637A2 (pt) 2009-08-17 2017-04-25 Memorial Sloan Kettering Cancer Center "compostos de ligação de proteína de choque térmico, composições, e métodos para preparar e usar os mesmos"
JP5941407B2 (ja) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
WO2011060253A2 (fr) 2009-11-13 2011-05-19 Myrexis, Inc. Méthodes de traitement de maladies, composés pharmaceutiques, compositions et formes pharmaceutiques
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use
US8669248B1 (en) * 2010-09-30 2014-03-11 John Montana Adenine inhibitors of HSP90
EP2694505B1 (fr) * 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Inhibiteurs de la hsp90
EP2694506B1 (fr) * 2011-04-05 2017-09-20 Sloan-kettering Institute For Cancer Research Inhibiteurs de hsp90
US8685966B2 (en) * 2011-04-08 2014-04-01 University Of Kansas GRP94 inhibitors
KR102196424B1 (ko) 2011-04-28 2020-12-30 슬로안-케테링인스티튜트퍼캔서리서치 Hsp90 병용요법
AU2012282903A1 (en) 2011-07-08 2014-02-13 Sloan-Kettering Institute For Cancer Research Uses of labeled HSP90 inhibitors
CN102319240A (zh) * 2011-07-19 2012-01-18 厦门大学 去乙酰真菌环氧乙酯作为Hsp90抑制剂的应用
US9738643B2 (en) * 2012-08-06 2017-08-22 Duke University Substituted indazoles for targeting Hsp90
WO2014144715A1 (fr) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Imagerie cardiaque à ciblage hsp90 et traitement associé
CA2921571C (fr) * 2013-08-16 2022-04-05 Memorial Sloan-Kettering Cancer Center Inhibiteurs selectifs de la grp94 et leurs utilisations
BR112016014758A8 (pt) * 2013-12-23 2020-06-02 Memorial Sloan Kettering Cancer Center composto e método para a marcação radioativa e composição farmacêutica compreendendo o referido composto
EP3131586A4 (fr) * 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Agents thérapeutiques cibles
MX2017003513A (es) * 2014-09-17 2017-07-28 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia.

Also Published As

Publication number Publication date
EP3194975A4 (fr) 2018-05-02
JP2017530961A (ja) 2017-10-19
EA201790444A1 (ru) 2017-08-31
EP3194975A1 (fr) 2017-07-26
CN107110869A (zh) 2017-08-29
CN107110869B (zh) 2021-08-10
MX2017003513A (es) 2017-07-28
WO2016044629A1 (fr) 2016-03-24
AU2015317632A1 (en) 2017-04-13
US20210308285A1 (en) 2021-10-07
AU2022202337A1 (en) 2022-04-28
US20200237934A1 (en) 2020-07-30
CA2961499A1 (fr) 2016-03-24
BR112017005313A2 (pt) 2017-12-05
AU2015317632B2 (en) 2022-01-13
US11065350B2 (en) 2021-07-20
JP6835709B2 (ja) 2021-02-24
US10617772B2 (en) 2020-04-14
KR20170052687A (ko) 2017-05-12
CN113521314A (zh) 2021-10-22
US20170304470A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
EP3641644A4 (fr) Système et procédé de diagnostic médical
EP3622407A4 (fr) Systèmes et méthodes de traitement de patients
EP3649962A4 (fr) Dispositif médical et procédé de traitement
NZ731467A (en) Anti-tim3 antibodies and methods of use
GB2544906B (en) Devices for treating vestibular and other medical impairments.
MX2016010677A (es) Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
MX2018015184A (es) Métodos para el diagnóstico de infecciones bacterianas y virales.
EP3294106A4 (fr) Dispositifs, procédés et systèmes permettant d'acquérir des informations de diagnostic médical et permettant la fourniture de services de santé à distance
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
EP3505091A4 (fr) Dispositif médical et méthode thérapeutique
EP3053619A4 (fr) Seringue médicale, joint utilisé pour une seringue et son procédé de fabrication
EP3258849A4 (fr) Dispositif de filtration d'une pompe médicale, ses procédés de fabrication et d'utilisation
GB2541571A (en) Pharmaceutical compositions
EP3452990A4 (fr) Systèmes et procédés de génération de diagnostics médicaux
EP3155971A4 (fr) Dispositif de diagnostic médical, procédé de fonctionnement d'un dispositif de diagnostic médical et programme de fonctionnement d'un dispositif de diagnostic médical
EP3505068A4 (fr) Dispositif de diagnostic médical et procédé de diagnostic médical l'utilisant
EP3275393A4 (fr) Dispositif d'observation médicale, dispositif d'observation chirurgicale et système d'observation médicale
EP3398633A4 (fr) Système de conception de dispositif d'administration, système d'administration, procédé de conception de dispositif d'administration, programme de conception de dispositif d'administration et système de conception de dispositif médical
EP3347844A4 (fr) Procédé et système pour diagnostiquer une maladie et générer des recommandations de traitement
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
EP3132420A4 (fr) Appareil d'imagerie médicale et son procédé de fonctionnement
EP3520724A4 (fr) Dispositif médical et méthode thérapeutique
EP3508148A4 (fr) Dispositif médical et méthode thérapeutique
EP3590438A4 (fr) Dispositif de commande d'affichage médical, dispositif d'observation médicale, procédé de commande d'affichage et système d'observation médicale